Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DP CD8 TIL · 1 trial · 6 indications
Frequency and severity of treatment-related adverse events as assessed by CTCAE v5.0 in participants treated with DP CD8 TIL adoptive cell therapy with and without ex vivo siRNA PD-1 modulation after lymphodepleting chemotherapy and followed by high-dose and low-dose IL-2.
| Arm | Type | Description |
|---|---|---|
| DP CD8 TIL | EXPERIMENTAL | Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 an CD103 and expanded in vitro. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion. |
| DP CD8 TIL KD | EXPERIMENTAL | Adoptive Cell Transfer of tumor infiltrating lymphocytes that were selected for tumor reactivity by the expression of cell surface proteins CD39 and CD103 and expanded in vitro in the presence of PH-762, a silencing RNA that reduces the expression of the checkpoint inhibitor PD-1. A suspension of 1-40 billion cells will be delivered one time by intravenous infusion. |
| Name | Type | Description |
|---|---|---|
| DP CD8 TIL | BIOLOGICAL | intravenous infusion of T cell suspension |
| DP CD8 TIL KD | BIOLOGICAL | intravenous infusion of T cell suspension |
| Low dose IL-2 | BIOLOGICAL | Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks |
Inclusion Criteria * Participants must have signed and dated a current IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. Patients must have the ability to understand a written informed consent document, and the willingness to sign it. * Conse...
DP CD8 TIL is an investigational adoptive cell therapy being studied for use in head and neck squamous cell carcinoma (HNSCC). It is also being evaluated in other solid tumors including melanoma, gynecologic cancer, colorectal cancer, lung cancer, and urogenital cancer as part of a Phase 1 clinical trial.
DP CD8 TIL is a monoclonal antibody-based therapy that uses cancer-specific CD8+ tumor infiltrating lymphocytes. The treatment involves adoptive cell therapy, where these lymphocytes are collected and used to target and attack tumor cells in patients with solid tumors.
DP CD8 TIL is being developed by Phio Pharmaceuticals Corp., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of this investigational therapy in patients with solid tumors.
DP CD8 TIL is currently in Phase 1 clinical development. It is an investigational drug that has not been approved by regulatory authorities. The ongoing trial is active but not recruiting participants, with an enrollment target of 18 patients.
DP CD8 TIL is being studied in a single Phase 1 clinical trial with the identifier NCT05902520. The trial is titled 'Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors' and is being conducted in the United States.
DP CD8 TIL is a specific investigational therapy developed by Phio Pharmaceuticals Corp. It is not known to have alternative names. The therapy uses CD8+ tumor infiltrating lymphocytes and is being studied in a Phase 1 trial for solid tumors.